From: The progress of targeted therapy in advanced gastric cancer
NCT code/trial name | Drugs | Setting | Masking | Primary endpoint | Arm | Status | Results | |
---|---|---|---|---|---|---|---|---|
PhaseIIIToGA/NCT01041404 | HER2 inhibitor | Trastuzumab | First line | Double blind | OS | Cisplatin + fluoropyrimidine + Trastuzumab vs. Placebo | Finished | Positive |
PhaseIIINCT01774786 | Pertuzumab | First line | Double blind | OS | Trastuzumab + cisplatin + fluoropyrimidine + Pertuzumab vs. Placebo | Ongoing | Unknown | |
Phase III/IIINCT01641939 | T-DM1 | Second line | Open label | OS | T-DM1 vs. Taxane | Ongoing | Unknown | |
PhaseIII TYTAN/NCT00486954 | Lapatinib | Second line | Open label | OS | Lapatinib vs. Paclitaxel | Finished | Negative | |
PhaseIII LOGiC/NCT00680901 | Lapatinib | First line | Double blind | OS | Capecitabine + oxaliplatin + Lapatinib vs. Placebo | Finished | Negative | |
PhaseIIIEXPAND/NCT00678535 | EGFR Inhibitors | Cetuximab | First line | Open label | PFS | Capecitabine and cisplatin + Cetuximab vs. Placebo | Finished | Negative |
PhaseIIIREAL-3/NCT01234324 | Panitumumab | First line | Open label | Frequency of pT3/T4 categories after surgery | EOX (epirubicin/oxaliplatin/capecitabine) | Ongoing | Unknown | |
PhaseIII AVAGAST/NCT00548548 | VEGF inhibitors | Bevacizumab | First line | Double blind | OS | Capecitabine + cisplatin + Bevacizumab vs. Placebo | Finished | Negative |
PhaseIII REGARD/NCT00917384 | Ramucirumab | Second line | Double blind | OS | and BSC + Ramucirumab vs. Placebo | Finished | Positive | |
PhaseIIIRAINBOW/NCT01170663 | Ramucirumab | Second line | Double blind | OS | Paclitaxel + Ramucirumab vs. Placebo | Ongoing | Unknown | |
PhaseIIINCT01246960 | Ramucirumab | First line | Double blind | PFS | mFOLFOX6+ Ramucirumab vs. Placebo | Ongoing | Unknown | |
PhaseIIINCT00970138 | Apatinib | Third line | Double blind | PFS | Placebo vs.Apatinib | Finishes | Positive | |
PhaseIIINCT01512745 | Apatinib | Third line | Double blind | PFS | placebo vs. apatinib | Ongoing | Unknown | |
PhaseIIINCT01747551 | Aflibercept | First line | Double blind | PFS | mFOLFOX6 + Aflibercept vs. Placebo | Ongoing | Unknown | |
PhaseIIINCT01152645 | c-MET inhibitor | Tivantinib (ARQ 197) | Second/Thirdline | Open label | DCR | Tivantinib | Finished | Modest efficacy |
PhaseIIINCT01662869 | Onartuzumab | First line | Double blind | OS | mFOLFOX6 + Onartuzumab vs. Placebo | Ongoing | Unknown | |
PhaseIIIGRANITE-1/NCT00879333 | m-TOR inhibitor | Everolimus (RAD001) | Second/third line | Double blind | OS | Everolimus vs. Placebo | Finished | Negative |